Items Tagged ‘Follicular Lymphoma’

August 16th, 2016

Opdivo® Highly Effective for Some Patients with Lymphomas

By

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal of Clinical Oncology. Lymphomas are a type of cancer that arise in immune cells. There are two main types of immune […]

View full entry

Tags: diffuse large B-cell lymphoma, Follicular Lymphoma, Lymphoma, News, nivolumab, Non-Hodgkin's Lymphoma, opdivo, peripheral T-cell lymphoma, T-Cell Non-Hodgkin's Lymphoma


June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


June 8th, 2016

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma

By

Genentech, announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL). The study compared Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan® (rituximab) plus chemotherapy followed by Rituxan alone. Results from […]

View full entry

Tags: Follicular Lymphoma, GALLIUM study, Gazyva, iNHL, News, nhl, Non-Hodgkin's Lymphoma, non-Hodgkin’s, rituxan, rituximab


December 17th, 2014

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

By

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, General HIV Related Cancers, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, hiv, hiv cancer, HIV Related Cancers, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, nhl


May 28th, 2014

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients

By

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy was deemed to be safe in this population. Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, b-cell lymphoma, dlbcl, Follicular Lymphoma, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma


September 4th, 2013

Celiac Disease Associated with Higher Risk of Lymphoma

By

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease is an autoimmune disorder of the small intestine characterized by intolerance to gluten, which is a […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, Health and Wellness, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, Screening/Prevention Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


February 8th, 2013

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma

By

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of a phase II study presented at the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego, California. Zevalin is […]

View full entry

Tags: Follicular Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


February 1st, 2013

Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma

By

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients with advanced stage follicular lymphoma, according to the results of a study presented at the 52nd annual meeting of the American Society of Hematology (ASH) in Orlando, Florida. […]

View full entry

Tags: Follicular Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


January 24th, 2013

Zevalin Effective in Follicular NHL Refractory to Rituximab

By

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results of a study published in the Journal of Clinical Oncology. Understanding Zevalin and RIT Zevalin therapy combines the monoclonal antibody Rituxan with Zevalin, which is comprised of an anti-CD20 monoclonal antibody […]

View full entry

Tags: Follicular Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, News, Non-Hodgkin's Lymphoma


January 10th, 2013

Consolidation with Zevalin Significantly Improves Progression-Free Survival in Advanced Follicular Lymphoma

By

Consolidation therapy with Zevalin® (ibritumomab tiuxetan) significantly prolongs progression-free survival and leads to high conversion rates from partial response to complete response in patients with advanced follicular lymphoma, according to the results of a study published in the Journal of Clinical Oncology. Understanding Zevalin and RIT Zevalin therapy combines the monoclonal antibody Rituxan® (rituximab) with Zevalin, […]

View full entry

Tags: Follicular Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma


March 14th, 2012

Lymphoma During Pregnancy Can Have Good Outcomes

By

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment until after delivery. These results were presented at the 2011 annual meeting […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma